A cell processing center (CPC) is a controlled facility where cells are processed for use in medical care. Its work can include culturing or otherwise preparing cells, quality control, and keeping manufacturing records. In Japan, the facility can be inside a hospital or clinic, elsewhere in Japan, or overseas; different regulatory routes apply to each setting Manufacturiungfacility.
The term describes a processing function, not proof that a treatment works. The processing facility, the medical institution providing treatment, and the evidence for that treatment are separate things to check.

What does a cell processing center do?
Processing means preparing cells, not simply storing a sample. Japan’s Ministry of Health, Labour and Welfare (MHLW) describes cell manufacturing as culturing or otherwise processing cells. Facility duties cover equipment, manufacturing and quality management, personnel, and records Manufacturiungfacility.
The steps depend on the cell source and intended product. When discussing a proposed treatment, ask the provider to explain what happens between sample collection and delivery: which processing steps are used, what tests are performed, how the cells are stored and transported, and how the batch remains linked to the intended recipient. Do not assume that every product is cultured or follows the same preparation process.
Quality controls address contamination, mix-ups, and other manufacturing problems. The applicable Japanese framework requires manufacturing and quality controls; the existence of those requirements is not evidence that a particular batch has met them Manufacturiungfacility.
Is a CPC the same as a treatment clinic?
No. A CPC identifies the cell-processing facility or function. A hospital or clinic may contain that facility, but a facility’s manufacturing status does not answer whether the proposed treatment is appropriate for you. Japan’s law separately addresses medical institutions providing regenerative medicine and facilities manufacturing specified processed cells 4980.
Ask whether the proposal is treatment under a filed treatment plan, use of an approved regenerative medical product for its approved indication, or participation in a clinical trial. Japan distinguishes the Act on the Safety of Regenerative Medicine framework from the Pharmaceuticals and Medical Devices Act framework for regenerative medical products. Charging for treatment is not what determines that distinction Manufacturiungfacility.
How are CPCs regulated in Japan?
For manufacturing specified processed cells under the regenerative-medicine safety framework, MHLW describes 3 facility routes. This overview excludes manufacture as regenerative medical products under the separate product framework Manufacturiungfacility.
| Facility setting | Route | Filing destination | PMDA survey for the application |
|---|---|---|---|
| Inside a hospital or clinic in Japan | Notification | Competent regional bureau of health and welfare | Not part of the notification route; legal duties still apply |
| Outside a medical institution, in Japan | Permission | MHLW | Yes |
| Outside Japan | Certification | MHLW | Yes |
The Pharmaceuticals and Medical Devices Agency (PMDA) describes its cell-processing-facility inspection role separately from GCTP inspections of regenerative medical product manufacturing sites. These are manufacturing oversight activities, not clinical findings of benefit 0003.
Permission must be renewed at the interval specified by Cabinet Order. Article 36 sets a statutory lower bound of 3 years for that interval; it does not say that renewal is required at least once every 3 years. Article 37 requires permitted manufacturers to notify MHLW within 30 days of changes to structure, equipment, or other specified matters 4980.
A facility number or certificate is not a treatment approval, a batch test result, or a guarantee of safety or benefit for an individual patient.
What does US registration mean?
US terminology and requirements are not interchangeable with Japan’s routes. Establishments manufacturing human cells, tissues, and cellular and tissue-based products (HCT/Ps) regulated solely under section 361 of the Public Health Service Act must register and list their products with FDA within 5 days of beginning operations, and update registration annually in December Tissue establishment registration.
21 CFR Part 1271 also addresses donor eligibility and current good tissue practice to reduce communicable-disease risks. Under section 1271.27, FDA’s acceptance of registration and listing does not establish regulatory compliance or mean that the product is licensed or approved Part 1271.
How can you check a proposed CPC?
Match the facility to the documents
Ask for the processing facility’s legal name, address, facility number, and applicable regulatory status. Compare those details with the current official record for that exact site, rather than relying on a certificate shown in a brochure. Japan’s amended regenerative-medicine safety framework took effect on May 31, 2025; an old screenshot should not substitute for a current check Index.
A practical document-checking scenario
Suppose a provider sends you a facility certificate before you agree to treatment. First compare its facility name and address with the place the provider says will process the cells. If they differ, ask for a written explanation. Next ask how your sample and the final batch will be identified, which release tests and acceptance criteria apply, who authorizes release, and what happens if a result falls outside those criteria.
A general facility certificate cannot answer those batch-specific questions. Before processing, ask for the planned checks; afterward, ask what results or a patient-facing release summary can be provided. This avoids expecting a completed batch report before the batch exists.
Keep clinical evidence separate
Even a satisfactory manufacturing record does not establish benefit for your condition. Ask for human evidence matching the disease and stage, cell type and source, dose, and delivery route. Check the study phase, sample size, comparison group, outcomes, follow-up period, and adverse events. Trial registration alone does not establish efficacy, and a result for one product or disease should not be treated as evidence for another.
What should you ask before treatment?
- What exact cell product is proposed, including its tissue source, whether it uses my own or donor cells, processing steps, dose, delivery route, and number of sessions?
- Which facility will process it, and how will identity, storage, transport, release checks, and handoffs be documented?
- What is the treatment’s regulatory status, and what human evidence supports this specific use?
- What are the known and potential risks, including infection, immune or tissue reactions, collection or delivery complications, and no benefit?
- What is included in the total treatment cost, including testing, processing, storage, repeat procedures, follow-up, and management of complications?
- Which clinician is responsible for follow-up, and whom should I contact if symptoms develop after I return home?
A licensed physician should assess suitability using your medical history, the proposed protocol, available evidence, risks, and alternatives. A processing facility’s status cannot replace that assessment.
The short answer
A cell processing center prepares and checks cells for medical use. It may be within a medical institution or at another site. Verify the processing facility, the proposed cell product, and the treatment evidence separately; a satisfactory answer about one does not settle the others.
Have questions about the proposed cell-processing arrangements?
Ask the patient support team how to request facility details and arrange a discussion with the treating clinician.
References
- MHLW, Japan. Specified processed cell manufacturing facilities: scope, facility routes, duties, and filing destinations. Official facility overview.
- Japanese Law Translation. Act on the Safety of Regenerative Medicine, including Articles 35–40 on manufacturing facilities. English statutory text.
- PMDA, Japan. GMP / QMS / GCTP Inspections, including the cell-processing-facility inspection system. Inspection overview.
- FDA. Tissue Establishment Registration: section 361 HCT/P registration, listing, and timing. Registration requirements.
- eCFR. 21 CFR Part 1271, including sections 1271.21 and 1271.27. HCT/P regulations.
- MHLW, Japan. Regenerative, cell, and gene therapy overview and amendment history. Regulatory framework overview.




